Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment.

Rodier M, Quirié A, Prigent-Tessier A, Béjot Y, Jacquin A, Mossiat C, Marie C, Garnier P.

PLoS One. 2015 Oct 15;10(10):e0140668. doi: 10.1371/journal.pone.0140668. eCollection 2015.

2.

Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.

Lawson TR, Brown IE, Westerkam DL, Blackhurst DW, Sternberg S, Leacock R, Nathaniel TI.

Restor Neurol Neurosci. 2015;33(3):301-8. doi: 10.3233/RNN-140480.

PMID:
25698111
3.

A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.

Yan X, Hu HT, Liu S, Sun YH, Gao X.

Neurol Res. 2015 Apr;37(4):352-8. doi: 10.1179/1743132814Y.0000000447. Epub 2014 Oct 8.

PMID:
25297471
4.

Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.

Röther J, Ford GA, Thijs VN.

Cerebrovasc Dis. 2013;35(4):313-9. doi: 10.1159/000348705. Epub 2013 Apr 23. Review.

5.

Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.

Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ.

J Stroke Cerebrovasc Dis. 2017 Sep;26(9):1996-2003. doi: 10.1016/j.jstrokecerebrovasdis.2017.06.010. Epub 2017 Jul 6.

6.

Exogenous t-PA administration increases hippocampal mature BDNF levels. plasmin- or NMDA-dependent mechanism?

Rodier M, Prigent-Tessier A, Béjot Y, Jacquin A, Mossiat C, Marie C, Garnier P.

PLoS One. 2014 Mar 26;9(3):e92416. doi: 10.1371/journal.pone.0092416. eCollection 2014.

7.

Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.

Williams JM, Navin TJ, Jude MR, Levi CR.

Aust J Rural Health. 2013 Aug;21(4):203-7. doi: 10.1111/ajr.12038.

PMID:
24033520
8.

The impact of acute kidney injury on in-hospital mortality in acute ischemic stroke patients undergoing intravenous thrombolysis.

Gadalean F, Simu M, Parv F, Vorovenci R, Tudor R, Schiller A, Timar R, Petrica L, Velciov S, Gluhovschi C, Bob F, Mihaescu A, Timar B, Spasovski G, Ivan V.

PLoS One. 2017 Oct 17;12(10):e0185589. doi: 10.1371/journal.pone.0185589. eCollection 2017.

9.

Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage.

Ji B, Zhou F, Han L, Yang J, Fan H, Li S, Li J, Zhang X, Wang X, Chen X, Xu Y.

Transl Stroke Res. 2017 Aug;8(4):334-340. doi: 10.1007/s12975-017-0526-6. Epub 2017 Feb 27.

10.

A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.

Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A.

Stroke. 2007 Jul;38(7):2173-5. Epub 2007 May 24.

PMID:
17525395
11.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

12.

Low Serum Levels of Brain-Derived Neurotrophic Factor Were Associated with Poor Short-Term Functional Outcome and Mortality in Acute Ischemic Stroke.

Wang J, Gao L, Yang YL, Li YQ, Chang T, Man MH, Zhang XY, Guo SC, Li LH.

Mol Neurobiol. 2017 Nov;54(9):7335-7342. doi: 10.1007/s12035-016-0236-1. Epub 2016 Nov 4.

PMID:
27815836
13.

[ASPECTS-DWI, arterial occlusion sites and subtype of acute ischemic stroke have a relation with outcome following intravenous rt-PA therapy].

Idei M, Sasaki T, Tanabe T, Muraoka K, Terada K, Meguro T, Hirotsune N, Nishino S.

No Shinkei Geka. 2012 Jul;40(7):585-91. Japanese.

PMID:
22728535
14.
15.

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

Adeoye O, Knight WA, Khoury J, Schmit PA, Sucharew H, Broderick JP, Pancioli AM; CLEAR-ER Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e313-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.012. Epub 2014 Feb 15.

16.

Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.

Mione G, Ducrocq X, Thilly N, Lacour JC, Vespignani H, Richard S.

Geriatr Gerontol Int. 2016 Jul;16(7):843-9. doi: 10.1111/ggi.12565. Epub 2015 Aug 5.

PMID:
26245693
17.

The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.

Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W.

Stroke. 2006 Dec;37(12):2957-62. Epub 2006 Oct 26.

PMID:
17068305
18.

Mild stroke: safety and outcome in patients receiving thrombolysis.

Logallo N, Kvistad CE, Naess H, Waje-Andreassen U, Thomassen L.

Acta Neurol Scand Suppl. 2014;(198):37-40. doi: 10.1111/ane.12235.

PMID:
24588505
19.

High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.

Hsu PJ, Chen CH, Yeh SJ, Tsai LK, Tang SC, Jeng JS.

Cerebrovasc Dis. 2016;42(1-2):117-21. doi: 10.1159/000445037. Epub 2016 Apr 19.

PMID:
27088493
20.

Intravenous tissue plasminogen activator for patients with minor ischemic stroke.

Huisa BN, Raman R, Neil W, Ernstrom K, Hemmen TM.

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):732-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.009. Epub 2011 Apr 30.

Supplemental Content

Support Center